This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit          

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Bevacizumab prolongs survival in advanced cervical cancer
USA Today
The drug bevacizumab helps women with advanced cervical cancer live nearly four months longer, according to a new study that's predicted to change the standard of care for the disease. Women who combined bevacizumab and chemotherapy lived a median of 17 months after diagnosis, while those who received chemo alone lived 13.3 months, according to a study of 452 women in the New England Journal of Medicine. Just two decades ago, women with advanced cervical cancer lived only eight or nine months, says lead author Krishnansu Tewari, a professor of gynecologic oncology at the University of California Irvine Medical Center.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Removing ovaries cuts risk of death in gene carriers
USA Today
Women who inherit mutations in high-risk genes that sharply increase the risk of breast or ovarian cancer can reduce their risk of death by 77 percent by having their ovaries removed by age 35, a new study shows. The study involved mutations in the genes BRCA1 and BRCA2, which cause 5 percent to 10 percent of breast cancers and 15 percent of ovarian cancers, according to the National Cancer Institute.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Previous CIN3 diagnosis doubled cervical, vaginal cancer mortality risk
Women previously treated for cervical intraepithelial neoplasia grade 3 were more than twice as likely to die from cervical or vaginal cancers than the general population, according to results of a population-based cohort study. Researchers conducted the study to identify the factors that influenced long-term risks for the development of or mortality from invasive cervical or vaginal cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  Work for the best

We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201.


HPV vaccination impacts lesion risk
HealthDay News via MPR
Vaccination with the quadrivalent human papillomavirus (HPV) vaccine is associated with reduced risk of atypia or worse (atypia+) or cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3), according to a study published online February 19 in the Journal of the National Cancer Institute. Birgitte Baldur-Felskov, M.D., from the Danish Cancer Society Research Center in Copenhagen, and colleagues assessed the risk of cervical lesions subsequent to HPV vaccination using data from nationwide registries for all girls and women born in Denmark from 1989–1999. Using linkage to the nationwide Pathology Data Bank, incident cases of cervical lesions were identified.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

A Medical
‘Must Have’

Morrow’s Gynecologic Cancer Surgery, 2nd Edition is an invaluable comprehensive surgical text book resource containing step-by-step written and illustrated descriptions of all the important operations in the field of gynecologic oncology.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Tom Crist at 972-402-7724.


Philadelphia hospital restricts morcellation procedure
The Wall Street Journal (Subscription requred)
Temple University Hospital has issued what appear to be the tightest restrictions yet on a common gynecological surgical procedure used during many hysterectomies, which has come under close scrutiny because of the potential to spread cancer in rare cases.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Circulating tumor DNA shows versatility in cancer screening and prognosis
BioNews Texas
Scientists from a number of institutions have found a promising new way to non-invasively screen for early-stage cancers using tiny fragments of DNA shed by tumors into the bloodstream. These circulating tumor DNA (ctDNA) strands were detected in more than 75 percent of patients studied by the team. The study consisted of 640 patients with various types of cancer, and the cancers that most often presented ctDNA were advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, liver, head, and neck.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Molecular tech helps doctors target cancer cells from the inside
A group of American researchers may have revolutionized how we treat cancer, thanks to molecular technology that can target diseased cells from the inside. The study tested the effect of nanomotors, miniscule devices that turn energy into motion, on live cells. Scientists found that they could potentially be used to deliver drugs non-invasively, or perform surgery inside of cells.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Feb. 19, 2014
Feb. 12, 2014
Feb. 5, 2014
Jan. 29, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063